On February 28, 2024, 180 Life Sciences Corp. reported the exercise of pre-funded warrants by a holder, resulting in the purchase of 64,684 shares of common stock at $0.0019 per share, amounting to $122.90 in cash. This transaction followed a 1-for-19 reverse stock split effective on the same date, as previously disclosed in a Current Report on Form 8-K filed with the SEC. The shares from the warrant exercise are to be issued and were exempt from registration under Section 4(a)(2) of the Securities Act, with their resale registered under a registration statement declared effective under the Securities Act. Post-issuance, the company's issued and outstanding common stock will total approximately 652,292 shares, not accounting for rounding from the reverse stock split. The report was signed by CEO James N. Woody, M.D., Ph.D., on March 1, 2024.

On February 28, 2024, 180 Life Sciences Corp. reported the exercise of pre-funded warrants by a holder, resulting in the purchase of 64,684 shares of common stock at $0.0019 per share, amounting to $122.90 in cash. This transaction followed a 1-for-19 reverse stock split effective on the same date, as previously disclosed in a Current Report on Form 8-K filed with the SEC. The shares from the warrant exercise are to be issued and were exempt from registration under Section 4(a)(2) of the Securities Act, with their resale registered under a registration statement declared effective under the Securities Act. Post-issuance, the company's issued and outstanding common stock will total approximately 652,292 shares, not accounting for rounding from the reverse stock split. The report was signed by CEO James N. Woody, M.D., Ph.D., on March 1, 2024.